{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:05:18Z","timestamp":1790255118040,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201306","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:12:03Z","timestamp":1784934723000},"page":"201306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergistic cell-cycle repression by HDAC\/EZH2 co-targeting in H3K27-altered diffuse midline glioma"],"prefix":"10.1016","volume":"34","author":[{"given":"Zili","family":"Zhen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukui","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4941-2260","authenticated-orcid":false,"given":"Shuai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7016-4922","authenticated-orcid":false,"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201306_bib1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201306_bib2","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/neuonc\/noaa024","article-title":"High-grade gliomas in adolescents and young adults highlight histomolecular differences from their adult and pediatric counterparts","volume":"22","author":"Roux","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201306_bib3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00401-014-1319-6","article-title":"Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications","volume":"128","author":"Buczkowicz","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.omton.2026.201306_bib4","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2017.75.9308","article-title":"Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries","volume":"36","author":"Hoffman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201306_bib5","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201306_bib6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1126\/science.1232245","article-title":"Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma","volume":"340","author":"Lewis","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201306_bib7","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccr.2013.10.006","article-title":"Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas","volume":"24","author":"Bender","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201306_bib8","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1101\/gad.217778.113","article-title":"The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression","volume":"27","author":"Chan","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.omton.2026.201306_bib9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nm.4293","article-title":"EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas","volume":"23","author":"Mohammad","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201306_bib10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: First Approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.omton.2026.201306_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00280-024-04658-4","article-title":"Pharmacology and pharmacokinetics of tazemetostat","volume":"93","author":"Orleni","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.omton.2026.201306_bib12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","article-title":"Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges","volume":"280","author":"Atadja","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omton.2026.201306_bib13","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ccell.2019.08.012","article-title":"Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas","volume":"36","author":"Krug","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201306_bib14","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1158\/2159-8290.CD-20-1065","article-title":"Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death","volume":"11","author":"Fresquet","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201306_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41392-022-01274-7","article-title":"Diffuse midline glioma treated with epigenetic agent-based immunotherapy","volume":"8","author":"Jing","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.omton.2026.201306_bib16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11060-021-03864-x","article-title":"Leptomeningeal disease in glioblastoma: endgame or opportunity?","volume":"155","author":"Akmal","year":"2021","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201306_bib17","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/cas.12691","article-title":"Nestin as a marker of cancer stem cells","volume":"106","author":"Neradil","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omton.2026.201306_bib18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.cell.2020.06.027","article-title":"Origins and Proliferative States of Human Oligodendrocyte Precursor Cells","volume":"182","author":"Huang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201306_bib19","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201306_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.stemcr.2025.102597","article-title":"Modeling glioma intratumoral heterogeneity with primary human neural stem and progenitor cells","volume":"20","author":"Liu","year":"2025","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.omton.2026.201306_bib21","doi-asserted-by":"crossref","first-page":"9505","DOI":"10.1523\/JNEUROSCI.1510-18.2018","article-title":"Molecular and Genetic Evidence for the PDGFRalpha-Independent Population of Oligodendrocyte Progenitor Cells in the Developing Mouse Brain","volume":"38","author":"Zheng","year":"2018","journal-title":"J. Neurosci."},{"key":"10.1016\/j.omton.2026.201306_bib22","article-title":"The genomic and transcriptional landscape of the spinal cord H3K27-altered diffuse midline glioma suggests the potential therapeutic strategy","author":"Xiao","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.omton.2026.201306_bib23","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.hlife.2024.07.004","article-title":"HiTIP-seq profiles epigenomic reprogramming of patient-derived diffuse midline glioma stem cells to epigenetic therapy","volume":"2","author":"Chen","year":"2024","journal-title":"hLife"},{"key":"10.1016\/j.omton.2026.201306_bib24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1126\/science.aao4750","article-title":"Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq","volume":"360","author":"Filbin","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201306_bib25","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccell.2019.09.005","article-title":"Re-programing Chromatin with a Bifunctional LSD1\/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG","volume":"36","author":"Anastas","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201306_bib26","doi-asserted-by":"crossref","first-page":"11929","DOI":"10.1523\/JNEUROSCI.1860-14.2014","article-title":"An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex","volume":"34","author":"Zhang","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.omton.2026.201306_bib27","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1042\/EBC20220025","article-title":"Oncofetal proteins and cancer stem cells","volume":"66","author":"Yan","year":"2022","journal-title":"Essays Biochem."},{"key":"10.1016\/j.omton.2026.201306_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw0064","article-title":"Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening","volume":"11","author":"Lin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201306_bib29","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/neuonc\/nou350","article-title":"Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma","volume":"17","author":"Lee","year":"2015","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201306_bib30","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/neuonc\/noaa062","article-title":"A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma","volume":"22","author":"Puduvalli","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201306_bib31","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/neuonc\/noad141","article-title":"Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047)","volume":"25","author":"Monje","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201306_bib32","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/s41588-021-00897-w","article-title":"Simultaneous disruption of PRC2 and enhancer function underlies histone H3.3-K27M oncogenic activity in human hindbrain neural stem cells","volume":"53","author":"Brien","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omton.2026.201306_bib33","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nm.3855","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201306_bib34","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/1541-7786.MCR-16-0389","article-title":"Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG","volume":"15","author":"Cordero","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.omton.2026.201306_bib35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neo.2015.12.002","article-title":"A Novel Mouse Model of Diffuse Intrinsic Pontine Glioma Initiated in Pax3-Expressing Cells","volume":"18","author":"Misuraca","year":"2016","journal-title":"Neoplasia"},{"key":"10.1016\/j.omton.2026.201306_bib36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ccell.2017.09.014","article-title":"H3.3(K27M) Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas","volume":"32","author":"Pathania","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201306_bib37","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccell.2021.01.005","article-title":"H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model","volume":"39","author":"Haag","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201306_bib38","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/0008-5472.CAN-22-1577","article-title":"Olig1\/2-Expressing Intermediate Lineage Progenitors Are Predisposed to PTEN\/p53-Loss-Induced Gliomagenesis and Harbor Specific Therapeutic Vulnerabilities","volume":"83","author":"Verma","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201306_bib39","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nature24014","article-title":"Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma","volume":"549","author":"Venkatesh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201306_bib40","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41419-020-02909-9","article-title":"The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status","volume":"11","author":"Chen","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omton.2026.201306_bib41","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2026.201306_bib42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","article-title":"ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays","volume":"347","author":"Hu","year":"2009","journal-title":"J. Immunol. Methods"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:37:51Z","timestamp":1790253471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001827"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201306","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic cell-cycle repression by HDAC\/EZH2 co-targeting in H3K27-altered diffuse midline glioma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201306"}}